Posters & Publications :: Cellectar Biosciences, Inc. (CLRB)

Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy.

Oct 15, 2019

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs, PLEs

CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sep 17, 2019

Iopofosine I 131

Preclinical pharmacokinetics and dosimetry studies of [<sup>124</sup>I/<sup>131</sup>I]-CLR1404 for treatment of pediatric solid tumors in murine xenograft models

Mar 29, 2019

Ian R Marsh

Targeted Delivery Platform, Iopofosine I 131, CLR 124, CLR1404

Combining internal delivery of radiation via CLR1404 with external beam radiation in head and neck cancer

Apr 25, 2018

Harari, Paul

Iopofosine I 131, CLR 124

Efficacy of fractionated injections of CLR 131 in an OPM-2 SCID nude mouse model

Apr 25, 2018

Longcor J Friend J

Iopofosine I 131

Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy

Apr 25, 2018

Longcor J Hoover R

PDCs